Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

• Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™

• Financing led by 3i, LP includes $16M debt financing for the purchase of assets and up to $75M in preferred convertible equity available for therapeutics commercialization and corporate growth initiatives

FREMONT, CA AND SAN ANTONIO, TX / ACCESS Newswire / December 11, 2025 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a diversified therapeutics company, today announced it has acquired the strategic manufacturing and development assets of Scorpius Holdings, Inc. and is launching Velocity Bioworks, a wholly owned subsidiary of Tivic, to provide contract development and manufacturing services to Tivic and other companies.

Strategic advantages of this acquisition and the formation of Velocity Bioworks include:

• Secures a robust US-based manufacturing site for Tivic's lead drug candidate Entolimod as the company moves towards a Biologics License Application (BLA) with the U.S. Food & Drug Administration.

• Strengthens our position to increase speed of development for other Entolimod and Entolasta indications in the pipeline, including neutropenia and advanced cancer treatments.

• Creates new revenue opportunities for Tivic via Velocity Bioworks' ability to serve other biotech companies. Under Tivic's leadership, Velocity Bioworks will focus on speed, value and high-quality production of cellular and biologic therapies.

In Q3, Tivic successfully validated the Entolimod cell line in the same site that is now Velocity Bioworks. This represented a major manufacturing milestone for Tivic by advancing the company along the path to cGMP, a prerequisite to commercialization.

"Tivic has entered a new era. With the licensing earlier this year of a Phase III biologic asset and our strategic expansion into biologics, the next logical step is bringing development and manufacturing capabilities in-house. This allows us to lower development costs and eliminate long wait times often associated with outsourcing. It also unlocks the potential for meaningful revenue through the launch of Velocity Bioworks-our new CDMO built for fast, high-quality biologic production that can serve both us and third-party biotech companies. More importantly, it positions Entolimod for rapid advancement toward a BLA and accelerates development across our oncology portfolio," stated Jennifer Ernst, Tivic CEO.